Noom GLP-1 review (2026): behavioral coaching + compounded meds, with history to know
Noom is the most recognized name in digital weight management, and Noom Med extends that into GLP-1 prescriptions. The behavioral infrastructure is genuinely strong. The recent history — a class action settlement and a terminated Lilly partnership — is context you should have before signing up.
Noom is the biggest name in digital weight management, and its GLP-1 program (Noom Med) brings that behavioral infrastructure to medication-assisted treatment, now spanning compounded semaglutide, a compounded tirzepatide tier, and a lower-cost microdose option. Standard semaglutide runs $249/mo and tirzepatide runs $299/mo, all-in, billed as a lump sum every 12 weeks rather than truly monthly — a detail worth planning around. The honest accounting: the program carries real baggage. A $62M class action settlement over subscription cancellation practices closed in 2023, and the Eli Lilly commercial partnership (for brand-name tirzepatide access) has ended — Noom's tirzepatide tier is a compounded equivalent, not the branded drug. If you want a well-known platform with behavioral coaching and you're comfortable with compounded medication, Noom Med is a reasonable choice. If you want the cheapest option or need brand-name GLP-1s, look elsewhere.
What you will actually pay
Dual-mechanism GLP-1/GIP with full coaching platform — medication + behavioral support
Standard GLP-1 with full coaching platform — medication + behavioral support
Lower starting dose for women who want a gentler on-ramp
Women wanting behavioral coaching without medication — not a GLP-1 program
Estimated all-in cost: ~$2,388–$3,588/yr across the three GLP-1 tiers (microdose to tirzepatide), billed quarterly. Does not include labs if ordered separately.
- ✓ Well-established brand with large user base
- ✓ Behavioral coaching platform is more developed than most GLP-1 telehealth competitors
- ✓ Microdose program offers a lower-cost entry point ($199/mo ongoing)
- ✓ Now offers a compounded tirzepatide tier (GLP-1Rx Plus), not just semaglutide
- ✓ All-in price: medication + clinical support + app, no separate membership fee
- ✓ Widespread name recognition simplifies insurance pre-authorization conversations
- ⚑ $62M class action settlement (2023) over difficult subscription cancellations — check current cancellation policy before enrolling
- ⚑ Eli Lilly commercial partnership ended — no brand-name Zepbound through Noom; its tirzepatide tier is a compounded equivalent, not the branded drug
- ⚑ Compounded GLP-1 only (not FDA-approved brand-name medication)
- ⚑ Billed as a lump sum every 12 weeks, not a true monthly charge — budget for roughly 3x the "per month" figure at once
- ⚑ Higher standard price ($249–299/mo) vs. Fridays annual plan (~$150–240/mo) or Mochi Health (~$178–278/mo all-in) for comparable or more clinical support
- ⚑ Noom's behavioral approach requires engagement — passive users may not get value from the platform premium
- ⚑ BBB complaint volume is high despite A+ rating; a May 2026 NAD review found Noom's microdose "smarter start" marketing claim unsubstantiated
What Noom Med is
Noom Med is the medication-assisted weight management arm of Noom, offering GLP-1 prescriptions alongside Noom's established behavioral coaching platform. The platform includes a psychology-based curriculum, daily lessons and check-ins, personal coaching, and — in the Noom Med program — clinical evaluation for GLP-1 medications. The integration of behavioral support with medication is the genuine differentiator; the clinical evidence supports combining behavioral intervention with GLP-1 therapy for better long-term outcomes than medication alone.
Pricing: what you actually pay
Noom Med has two main GLP-1 tiers:
- Standard program (compounded semaglutide or tirzepatide): ~$279/mo. Includes medication, clinical visits, and full Noom coaching platform.
- Microdose semaglutide: $79–$179/mo. Sub-therapeutic doses for women who want a gentler titration or a lower entry price.
- Noom behavioral only (no medication): ~$70/mo. The core habit-change platform without GLP-1 prescription.
At $279/mo, the standard program is on the higher end for compounded GLP-1 telehealth. Fridays' annual semaglutide plan is ~$150/mo, Mochi Health is ~$178/mo. The premium at Noom is the behavioral platform — if you would genuinely use the coaching curriculum, the value calculation shifts in Noom's favor. If you just want the medication, cheaper options exist.
The Eli Lilly partnership: what it was and why it ended
Noom previously had a commercial partnership with Eli Lilly to offer brand-name Zepbound (tirzepatide) through the Noom Med platform. This partnership has since ended. The most likely reason is Lilly's decision to invest in its own LillyDirect self-pay program — offering Zepbound vials directly to patients at $299–$449/mo undercut the need for a telehealth intermediary for brand-name access. Noom Med now operates with compounded GLP-1 medications. This is a meaningful change for women who specifically wanted brand-name Zepbound through Noom.
The $62M class action: what it was and what it means now
In 2023, Noom settled a class action lawsuit for $62M. The suit alleged that Noom made it difficult for users to cancel subscriptions that auto-renewed — specifically, that the cancellation process was designed to retain subscribers against their intent. The settlement closed the litigation, and current practices may have changed. What it means for you: read the current cancellation terms before enrolling, confirm how auto-renewal works, and don't rely on Noom's track record on subscription practices being seamlessly customer-friendly.
Who Noom Med is for in perimenopause
Noom Med is a weight management platform, not a menopause-care platform. The GLP-1 medications address perimenopausal metabolic changes — insulin resistance, visceral fat, appetite disruption — regardless of whether the provider has hormone expertise. But Noom does not offer HRT or hormonal evaluation. Women who want to address both the hormonal root and the metabolic consequence in one relationship should look at platforms that offer both, like Alloy or Midi Health.
Noom Med works best for women who: are engaged with the behavioral curriculum (the app is genuinely useful if you use it), want a single platform to manage GLP-1 treatment and behavioral support, and are comfortable with compounded medication.
Frequently asked questions
Does Noom offer GLP-1 medications?+–
Yes, through Noom Med. The program includes compounded semaglutide (standard and microdose tiers) and a compounded tirzepatide tier called GLP-1Rx Plus. The partnership with Eli Lilly for brand-name tirzepatide (Zepbound) has ended, so Noom operates entirely with compounded GLP-1 medications, not branded ones.
What happened with the Noom class action lawsuit?+–
Noom settled a $62M class action lawsuit in 2023 related to subscription cancellation practices — specifically, allegations that Noom made it difficult for users to cancel auto-renewing subscriptions. The settlement does not mean current practices are the same, but it is a documented concern. Read the current cancellation terms carefully before enrolling and especially before agreeing to any auto-renewal.
Is Noom Med worth $249–299/mo?+–
Compared to competitors: Fridays offers compounded semaglutide with dietitian and coaching bundled for ~$249/mo (month-to-month) or ~$150/mo (annual). Mochi Health runs ~$178/mo all-in with obesity-medicine physicians. Noom Med's $249–299/mo is on the higher end for compounded GLP-1, and it's billed quarterly rather than monthly. If you specifically value Noom's behavioral coaching app and psychology-based curriculum, the premium may be worth it. If you primarily want the medication and basic clinical support, cheaper options exist.
Is Noom Med good for perimenopause weight gain?+–
Noom Med is a weight management platform, not a menopause-care platform. The GLP-1 medication works for hormonal weight gain regardless of the provider's specialization, but Noom does not offer HRT or hormone evaluation. For women who want both GLP-1 treatment and hormonal management in one platform, Alloy or Midi Health are better suited.